Antoniou Tony, Smith Graham, Su Desheng, Raboud Janet M, Lee Derek, Kovacs Colin, Brunetta Jason, Fletcher David, Crouzat Fred, Loutfy Mona
1University of Toronto, Toronto, Ontario, Canada.
J Int Assoc Physicians AIDS Care (Chic). 2012 May-Jun;11(3):192-7. doi: 10.1177/1545109711424967. Epub 2012 Jan 13.
To compare the immunologic effectiveness of raltegravir-maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M-) in treatment-experienced patients in clinical practice.
We conducted a retrospective study of treatment-experienced HIV-infected adults receiving either R+M+- or R+M--based therapy. Longitudinal CD4 counts were analyzed using a linear mixed model.
One hundred and fifty-six patients were included in the analysis, of whom 32 were receiving R+M+ and 124 R+M-. Mean baseline CD4 counts in patients on R+M+ and R+M- were 463.8 and 442.3 cells/mm(3), respectively (P = .67). In multivariable mixed models, a baseline viral load ≥50 copies/mL was significantly associated with CD4 change during follow-up (P < .0001). No difference between R+M+ and R+M- was observed during follow-up (P = .81).
CD4 cell recovery was similar among patients receiving either R+M+- or R+M--based therapy during a 24-month period of follow-up.
在临床实践中，比较基于雷特格韦-马拉维罗克（R+M+）方案与不包含马拉维罗克的基于雷特格韦方案（R+M-）在经治患者中的免疫效果。
我们对接受R+M+或R+M-治疗的经治HIV感染成人进行了一项回顾性研究。使用线性混合模型分析纵向CD4细胞计数。
156例患者纳入分析，其中32例接受R+M+治疗，124例接受R+M-治疗。接受R+M+和R+M-治疗患者的平均基线CD4细胞计数分别为463.8和442.3个细胞/mm³（P = 0.67）。在多变量混合模型中，基线病毒载量≥50拷贝/mL与随访期间的CD4变化显著相关（P < 0.0001）。随访期间未观察到R+M+和R+M-之间存在差异（P = 0.81）。
在24个月的随访期内，接受R+M+或R+M-治疗的患者CD4细胞恢复情况相似。
